Archives


Rate this Article: (1) Votes

  Review Article

Year : 2016 | Volume: 1 | Issue: 3 | Pages: 71-80

DRY POWDER NANOPARTICLES FOR THE TREATMENT OF ASTHMA

Venugopalaiah. P*, Dr. B.Kumar, Dr.M.Gobinath, D.Sravanthi

* Corresponding author

  • Ratnam Institute of Pharmacy, Pidathapolur, Nellore-524346, Andhra Pradesh, India

  28/02/2016

  06/03/2016

  14/03/2016

  10/05/2016

  • Venugopalaiah. P*, Dr. B.Kumar, Dr.M.Gobinath, D.Sravanthi

    , (2016), DRY POWDER NANOPARTICLES FOR THE TREATMENT OF ASTHMA. International Journal of Pharmacometrics and Integrated Biosciences, 1(3): 71-80. doi: 0

Abstract

Pulmonary drug delivery was found to be a targeted drug delivery to lungs for the treatment of lung related disorders. Recent advancements in pulmonary drug delivery include inhalation of drug products in the form of nanoparticles. Inhalation of nanoparticle based drugs leads to direct ingress to lungs where as systemic side effects and high doses of drugs can be excluded through pulmonary drug delivery. Hence this type of drug delivery system can be a best system for the treatment of asthma which was found to be a chronic disease from centuries. Increased interest in pulmonary drug delivery in recent years may be due to provision of large surface area of the lung (approx 140 m2), avoids first pass metabolism while improving bioavailability of drugs. Nanoparticle based treatment improves the site specific action of drugs by controlling the particle size and surface properties. Nanoparticles also provide free passage of drugs to lungs without blocking the airways, thereby increasing patient compliance. Current review focuses on formulation, applications, characterization, various technologies and devices employed in the preparation of nanoparticle based pulmonary drug delivery system.

Keywords

Nanoparticles, Pulmonary drug delivery, Asthma, Dry powder inhalers, Insufflators etc